Novel Treatments in Lupus

Purpose of Review: The standard treatment options for systemic lupus erythematosus (SLE) are focused on non-specific immunosuppression. Over the past few years, scientific studies and ongoing clinical trials have shifted the paradigm with rapid advances in developing biologics and small molecules. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Vukelic, Milena, Li, Yi, Kyttaris, Vasileios C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262343/
https://www.ncbi.nlm.nih.gov/pubmed/30524430
http://dx.doi.org/10.3389/fimmu.2018.02658
_version_ 1783375083881889792
author Vukelic, Milena
Li, Yi
Kyttaris, Vasileios C.
author_facet Vukelic, Milena
Li, Yi
Kyttaris, Vasileios C.
author_sort Vukelic, Milena
collection PubMed
description Purpose of Review: The standard treatment options for systemic lupus erythematosus (SLE) are focused on non-specific immunosuppression. Over the past few years, scientific studies and ongoing clinical trials have shifted the paradigm with rapid advances in developing biologics and small molecules. A number of monoclonal antibodies and small molecule inhibitors have been developed to target specific pathways involved in SLE. Many of these novel therapeutic agents are already being tested in clinical trials and they may 1 day reshape the landscape of SLE treatment. Herein we review potential future therapeutic options for SLE.
format Online
Article
Text
id pubmed-6262343
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62623432018-12-06 Novel Treatments in Lupus Vukelic, Milena Li, Yi Kyttaris, Vasileios C. Front Immunol Immunology Purpose of Review: The standard treatment options for systemic lupus erythematosus (SLE) are focused on non-specific immunosuppression. Over the past few years, scientific studies and ongoing clinical trials have shifted the paradigm with rapid advances in developing biologics and small molecules. A number of monoclonal antibodies and small molecule inhibitors have been developed to target specific pathways involved in SLE. Many of these novel therapeutic agents are already being tested in clinical trials and they may 1 day reshape the landscape of SLE treatment. Herein we review potential future therapeutic options for SLE. Frontiers Media S.A. 2018-11-16 /pmc/articles/PMC6262343/ /pubmed/30524430 http://dx.doi.org/10.3389/fimmu.2018.02658 Text en Copyright © 2018 Vukelic, Li and Kyttaris. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Vukelic, Milena
Li, Yi
Kyttaris, Vasileios C.
Novel Treatments in Lupus
title Novel Treatments in Lupus
title_full Novel Treatments in Lupus
title_fullStr Novel Treatments in Lupus
title_full_unstemmed Novel Treatments in Lupus
title_short Novel Treatments in Lupus
title_sort novel treatments in lupus
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262343/
https://www.ncbi.nlm.nih.gov/pubmed/30524430
http://dx.doi.org/10.3389/fimmu.2018.02658
work_keys_str_mv AT vukelicmilena noveltreatmentsinlupus
AT liyi noveltreatmentsinlupus
AT kyttarisvasileiosc noveltreatmentsinlupus

Ejemplares similares